0707 ET - After a bruising 2024, CVS shares continue to rebound after the healthcare giant's 4Q results top Wall Street expectations. The company reports revenue up 4% at $97.7 billion, beating analyst targets. The top line was boosted by growth in CVS's healthcare benefits and pharmacy segments, offset slightly by a decline in its health service segment. Quarterly adjusted earnings of $1.19 a share cleared analyst forecasts for 91 cents a share. The company's earnings guidance for 2025 is in line with current estimates. Shares rise 9% to $59.71 premarket. (dean.seal@wsj.com)
(END) Dow Jones Newswires
February 12, 2025 07:07 ET (12:07 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.